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The tryptophan metabolism enzyme, L-kynureninase, is a novel inflammatory factor in pso-
riasis and other inflammatory diseases
JL Harden,1 SM Lewis,1 S Lish,1 M Suarez-Farinas1, 2, D Gareau,1 T Lentini,1 L Johnson-
Huang,1 JG Krueger1 and M Lowes1, 3 1 Laboratory for Investigative Dermatology, The 
Rockefeller University, New York, NY, 2 Center for Clinical and Translational Science, The 
Rockefeller University, New York, NY and 3 Division of Dermatology, Montefiore Medical 
Center, Albert Einstein College of Medicine, Bronx, NY
L-kynureninase (KYNU), an enzyme in the tryptophan metabolism pathway, is habitually found as 
a differentially expressed gene (DEG) in psoriasis. Although many DEGs have known function in 
regards to psoriasis and inflammation, KYNU has been completely unexplored in both psoriasis and 
within general immunology. Here we show that psoriatic lesional skin has significantly increased 
KYNU mRNA, and is infiltrated by large numbers of KYNU+ cells, as determined by qRT-PCR and 
immunohistochemistry, respectively. The identity of KYNU+ cells was elucidated using both two-
color immunofluorescence and qRT-PCR. Although KYNU is expressed in several cell lineages, 
myeloid subsets were found to express 100-fold more KYNU compared to all other cell types, sug-
gesting a likely immunomodulatory role for this enzyme. To determine how KYNU may contribute 
to inflammation, primary human cutaneous cells were cultured with specific tryptophan metabolites, 
and modulation of gene expression was assessed. Interestingly, metabolites downstream of KYNU 
induced significant upregulation of several inflammatory genes (including IL-20, IL-8, CCL2, CXCL1, 
VCAM, ICAM, and E-selectin), with the metabolite directly produced by KYNU (3-hydroxyanthra-
nilic acid) inducing the highest amount of inflammatory gene upregulation. Conversely, metabolites 
upstream of KYNU (such as the AhR-ligand, kynurenine) had minimal ability to induce and even 
suppressed expression of some inflammatory genes. Therefore, KYNU may be a pivotal switch in 
tryptophan metabolism and dictate an inflammatory outcome. By mining gene array data, we found 
many other human diseases, including atopic dermatitis and lupus, also contain elevated KYNU, 
suggesting a role of this enzyme not only in psoriasis, but also in general cutaneous inflammation.   
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Predictors of skin disease outcome in rituximab-treated refractory dermatomyositis patients
JM Olazagasti,1 C Crowson,1 MS Hein,1 C Lopez de Padilla,1 R Aggarwal,2 CV Oddis2 and 
AM Reed3 1 Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, 
MN, 2 Division of Rheumatology, Department of Medicine, University of Pittsburgh, 
Pittsburgh, PA and 3 Department of Pediatrics, Duke University School of Medicine, Durham, 
NC
The purpose of the study was to identify clinical and laboratory predictors of skin disease outcome 
in patients with refractory dermatomyositis (DM) treated with rituximab. We analyzed data for 116 
DM patients (68 with adult DM and 48 with juvenile DM) in the Rituximab in Myositis trial. Skin 
disease outcome was defined as the absolute change from baseline to 24 weeks in the Cutaneous 
Disease Activity visual analog scale (VAS) score where a negative change indicated improvement 
and a positive change indicated worsening. We analyzed the association of the following baseline 
variables with skin disease outcome: demographics, dermatomyositis subtype, clinical and labora-
tory parameters, myositis autoantibodies (antisynthetase, anti–Mi-2, other autoantibodies, and no 
autoantibodies), and interferon (IFN)-regulated chemokines. Multivariable linear regression models 
were developed using stepwise variable selection methods. A multivariable model to predict skin 
disease outcome was built with good predictive ability (adjusted R2=0.33). The model included 
three factors at baseline: Cutaneous Disease Activity VAS score (b [regression coefficient] = -0.48, 
P < 0.01), Constitutional Disease Activity VAS score (b = 0.20, P 0.02), and anti–Mi-2 status (b = 
-5.71, P < 0.01). This indicates that participants with higher Cutaneous Disease Activity VAS scores 
at baseline were more likely to improve in their Cutaneous Disease Activity VAS scores from baseline 
to 24 weeks, participants with higher Constitutional Disease Activity VAS scores at baseline were 
more likely to worsen, and participants with positive anti–Mi-2 status at baseline were more likely 
to improve. This model could be clinically useful to optimize treatment selection in DM patients 
with recalcitrant skin disease.    
051
TNF-α antagonist induced cutaneous lupus
EC Milam, S Ramachandran and AG Franks The Ronald O. Perelman Department of 
Dermatology, NYU School of Medicine, New York, NY
TNF-α antagonist-induced lupus-like syndrome (TAILS) is a rare entity characterized by exposure 
to a TNF-α inhibitor, ≥1 new symptom of lupus erythematosus (LE), no prior history of LE, and 
symptom resolution upon medication discontinuation. It is more common in women in their fifties 
and among infliximab users. Cutaneous involvement can include malar rash, photosensitivity, 
subacute cutaneous LE (SCLE), and discoid lupus-type lesions. We present a case of a 57-year-old 
female receiving infliximab infusions for rheumatoid arthritis (RA) who presented with an 8-month 
history of a progressively worsening facial eruption. Physical exam revealed periorbital edema, with 
erythematous papules and plaques on the cheeks and forehead. Review of systems was otherwise 
negative. The patient noted the eruption initially coincided with a new-onset pneumonia. Punch 
biopsies revealed superficial and deep perivascular and interstitial mixed-cell inflammatory infil-
trates comprised predominately of lymphocytes and histiocytes, with occasional neutrophils and 
increased dermal mucin, consistent with a connective tissue disease process. Labs revealed ANA 
of 1:640 (homogenous pattern) and elevated dsDNA. The facial eruption improved upon discon-
tinuation of infliximab and initiation of chloroquine, and autoantibodies normalized. Thereafter, 
her RA was successfully managed by abatacept without lesion recurrence. While the pathogenesis 
of TAILS is not entirely understood, one proposed mechanism is that relative immunosuppression 
encourages increased infection rates and activation of polyclonal B lymphocytes, which stimulates 
autoantibody production.1 This case may be a clinical illustration of this mechanism, as the patient 
developed a rash and autoantibodies consistent with cutaneous LE while on a TNF-α inhibitor and 
soon after infection, with resolution upon antimalarial therapy and discontinuation of infliximab.   
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Dermal vascular changes in the C3H/HeJ alopecia areata mouse model
LE King,1 KA Silva,2 VE Kennedy,2 TM Stearns3 and JP Sundberg2 1 Division of Dermatology, 
Vanderbilt University, Nashville, TN, 2 Department of Research and Development, The 
Jackson Laboratory, Bar Harbor, ME and 3 Department of Computational Sciences, The 
Jackson Laboratory, Bar Harbor, ME
Mouse models with various types of inflammatory skin disease are often accompanied by increased 
angiogenesis as is the case for the flaky skin (Ttc7fsn) and chronic proliferative dermatitis (Sharpincpdm; 
Sharpincpdm-Dem) models. The C3H/HeJ inbred strain spontaneously develops alopecia areata (AA), 
a cell mediated autoimmune disorder which can be controllably expanded using full thickness 
skin grafts to young unaffected mice. This provides a reproducible and progressive model for AA in 
which the vascularization of the skin can be examined. Mice receiving skin grafts from AA or sham 
surgery were evaluated at 5, 10, 15, and 20 weeks after engraftment. Blood vessels were found 
to be slightly more numerous and dilated compared to controls by immunohistochemistry. This 
was more pronounced using antibodies directed against smooth muscle actin isoforms than CD31. 
Lymphatics are often overlooked as they are small slit-like dermal structures above the angle of the 
hair follicles. These lymphatics are often missed as they resemble artifactual separation of collagen 
bundles with some fixatives. Lymphatics are easily detected using LYVE1 by immunohistochemistry 
to label their endothelial cells. Using LYVE1 there were no changes in distribution or numbers of 
lymphatics although they were more prominent (dilated) in the mice with alopecia areata. Lyve1 
transcripts were not significantly upregulated except at 10 weeks after skin grafting when clinical 
signs of AA first become apparent. Other genes involved with vascular growth and dilation were 
dysregulated. These findings emphasize aspects of AA not commonly considered in the evaluation 
of human and other species affected.    
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Langerhans cells promote the development of imiquimod-induced psoriasis-like dermatitis 
by producing IL-23
S Sun, C Xiao and W Li Dermatology, Xijing Hospital, The Fourth Military Medical University, 
Xi’An, China
Psoriasis is an autoinflammatory skin disease that involves interplay among several types of cells, 
including keratinocytes, T cells anddendritic cells (DCs); however, the role ofLangerhans cells 
(LCs),specificsubset of DCsin epidermis, in the pathogenesis of psoriasis is not clear. In the present-
study, we treated C57BL/6 mice with imiquimod (IMQ)over 5 consecutive days to induce psoriatic-
dermatitis, and responses of LCs were analyzed subsequently. The number of LCs in the epidermis 
increased after IMQ treatment, and theproliferation level of LCs after IMQ treatment was higherthan 
that of LCs under steady state. LCs showed a phenotype of maturation by expressing higher level 
of MHC-II, CD86, CD80, CD40 after IMQ treatment. There was also elevated level of langerin on 
LCs after IMQ stimulation. LCs expressed increased level of IL-23, as indicated by intracellular 
staining and RT-PCR for the sorted LCs from the epidermis of IMQ-treated skin. Migration of LCs 
was accelerated after IMQ treatment, and there was increased number of LCs in the draining lymph 
node, which showed the phenotype of maturation by expressing higher level of CD86, CD80 and 
CD40. In regional lymph node, LCs also expressed higher level of PD-L1 and PD-L2 after IMQ 
treatment.In addition, LCswere sortedfrom naive C57BL/6 mice and were cultured for 24h with IMQ, 
and significantly increasedexpression ofIL-23was observed.Taken together, ourstudyshowedthat 
LCs promote the development of IMQ-induced psoriasis-like dermatitis by producing IL-23, and 
targeting LCs might be a future strategy for the treatment of psoriasis.    
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Essential requirement for IRF7 in the production of autoantibodies in murine lupus
F Miyagawa and H Asada Dermatology, Nara Medical University, Kashihara, Japan
Systemic lupus erythematosus (SLE) is considered to be the prototypic systemic autoimmune disease 
characterized by the production of autoantibodies against nuclear components. Recent genetic 
studies of SLE patients have revealed that interferon regulatory factor (IRF) 7 gene polymorphisms 
are associated with an increased risk of SLE but the precise role of IRF7 in SLE development is not 
fully understood. IRF7 is a member of the IRF family of transcription factors that induce transcription 
of IFN-α and the expression of interferon (IFN)-stimulated genes (ISGs). To investigate the role of 
IRF7 in the pathogenesis of SLE, a murine model of SLE induced by 2,6,10,14-tetramethylpen-
tadecane (TMPD) was used. IRF7 deficient mice and wild-type (WT) control mice were treated 
intraperitoneally with TMPD and spleens, kidneys and blood were harvested 2 weeks or 10 months 
later. Proteinuria was detected on dipstick analysis in both WT and IRF7 deficient mice and direct 
immunofluorescence of the kidneys revealed glomerular IgG deposits in both strains to the similar 
extent. Interestingly, anti-dsDNA, ssDNA, RNP and Sm autoantibodies were not detected by ELISA 
in the sera from IRF7 deficient mice but were present in the sera from WT mice. Real-time PCR 
showed that spleen cells from IRF7 deficient mice expressed substantially lower levels of ISGs as 
compared with WT mice. However, NF-κB target genes were upregulated in both strains suggesting 
that type I IFN pathway was critical in autoantibody production but NF-κB activation was sufficient 
for development of glomerulonephritis. These results demonstrate a specific requirement for IRF7 
in autoantibody production against the DNA- and RNA-containing antigens and autoantibody 
production and lupus nephritis are controlled by separate mechanisms in this model.    
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Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus 
psoriasis
T Czarnowicki,1 J Gonzalez,1 A Shemer,2 M Suarez-Farinas,1 JG Krueger1 and E Guttman-
Yassky3, 1 1 Investigative Dermatology, The Rockefeller University, New York, NY, 2 
Dermatology, Tel-Hashomer Hospital, Tel Aviv, Israel and 3 Dermatology, Icahn School of 
Medicine at Mount Sinai, New York, NY
Atopic dermatitis (AD) and psoriasis are characterized by T-cell infiltration in skin lesions, but their 
comparable systemic T-cell activation is unclear. We compared T-cell activation and cytokine 
producing cell-frequency in blood of adult AD and psoriasis patients using flow-cytometry. We 
measured cytokines, T-regulatory cells (Tregs) and T-cell activation markers in central and effector 
memory (Tcm and Tem) skin homing/cutaneous lymphocyte antigen (CLA+) and CLA- subsets from 
24 psoriasis patients, 35 AD patients and 13 controls. Early (CD69), mid (ICOS) and late (HLA-DR) 
activation markers were quantified in Tcm (CCR7+CD45RO+) and Tem (CCR7-CD45RO+) popula-
tions. AD showed higher frequency of CLA+ “polar” T-cell subsets (p<0.0001). In both diseases, CLA+ 
T-cells were significantly more activated compared to respective CLA- subsets (p<0.01), suggesting 
their prominent role in inflammatory skin diseases. AD demonstrated higher levels of ICOS/HLA-DR 
activation in circulating CLA+ and CLA- memory subsets (p<0.01). CD69 was the only activation 
marker that was higher in psoriasis (p=0.001), whereas ICOS expression was significantly higher 
in AD (p<0.0001), compatible with their respective roles in Th17 and Th2 responses. Significant 
correlations with SCORAD were observed in AD, particularly striking for ICOS (r=0.5, p<0.01). 
Higher CD25+CD127-CCR4+CLA+ Tregs were found in AD, correlating with SCORAD and IgE. 
Compared with psoriasis, AD is characterized by increased polar differentiation of Tcm/Tem sub-
sets, with higher, and persistent activation particularly within skin homing subsets. Higher systemic 
activation in AD might reflect the wide abnormalities seen in non-lesional skin in AD compared 
to psoriasis, emphasizing the large need for systemic treatment approaches for severe AD patients.   
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Ajulemic acid, a novel cannabinoid, suppresses the secretion of tumor necrosis factor alpha 
and interferon alpha from the peripheral blood mononuclear cells of dermatomyositis patients 
in vitro
ES Robinson1, 2, 3, M Bashir1, 2, P Alves1, 2, N Khan1, 2, J Tiao1, 2, LG Okon1, 2, J Okawa1, 2, 
R Feng4 and V Werth1, 2 1 VAMC, Philadelphia, PA, 2 Dermatology, UPenn, Philadelphia, PA, 
3 Columbia Univ, New York, NY and 4 Biostatistics and Epidemiology, UPenn, Philadelphia, 
PA
Ajulemic acid (AJA) is a synthetic, non-psychoactive analog of a metabolite of tetrahydrocannab-
inol with anti-inflammatory properties potentially useful for treating autoimmune skin disease. 
Experiments presented here quantified the capacity of AJA to suppress the secretion of tumor 
necrosis factor alpha (TNFα) and interferon alpha (IFN-α), cytokines implicated in the pathogenesis 
of dermatomyositis (DM), from peripheral blood mononuclear cells (PBMCs) isolated from patients 
with DM. The PBMCs were incubated with 3, 10 and 15 μM AJA with or without stimulation by 
lipopolysaccharide (LPS) in the case of TNFα or CpG oligodeoxynucleotides (CPG) in the case of 
IFN-α. ELISA was used to quantify the PBMCs’ secretion of TNFα and IFN-α. Unstimulated PBMCs 
incubated with 3 (n=13), 10 (n=16) and 15 (n=13) μM AJA reduced secretion of TNFα by a median 
(interquartile range) of 27.1% (-55.4% – 76.5%), 23.4% (-51.6% – 76.6%) and 83.9% (29.9% – 
96.1%), respectively, compared to unstimulated PBMCs without AJA incubation. Unstimulated 
PBMCs produced insignificant levels of IFN-α. LPS-stimulated PBMCs that were incubated with 
3 (n=16), 10 (n=16) and 15 (n=15) μM AJA reduced secretion of TNFα by a median (interquartile 
range) of -48.3% (a net increase; -101.1% – 13.9%), 75.9% (29.8% – 96.7%) and 95.4% (68.8% 
– 99.5%), respectively, compared to LPS-stimulated PBMCs that were not incubated with AJA. The 
median (interquartile range) quantity of IFN-α secreted from CPG-stimulated PBMCs incubated with 
3 (n=7), 10 (n=8) and 15 (n=7) μM AJA compared to those with no AJA incubation decreased by 
93.4% (82.8% – 99.7%), 99.6% (98.3% – 100.0%) and 100.0% (99.8% – 100.0%), respectively. 
AJA suppressed secretion of TNFα and IFN-α from the stimulated PBMCs of DM patients in vitro. 
Thus, AJA may offer a novel, and potentially less toxic, treatment for DM.    
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Peripheral blood gene expression identifies systemic pathways and processes in chronic 
cutaneous lupus erythematosus (CCLE) 
R Dey-Rao and AA Sinha Dermatology, University at Buffalo, Buffalo, NY
Lupus erythematosus (LE) is an autoimmune systemic disease with confounding etiology and patho-
genesis. Cutaneous lesions develop in 80% of LE patients at some point and 10-40% patients with 
cutaneous LE (CLE) show transitions to systemic LE (SLE). Major gaps remain regarding pathogenetic 
mechanisms underlying the development of cutaneous lesions in lupus. As systemic changes are 
likely to underlie skin specific manifestation, we analyzed global gene expression by microarray in 
peripheral blood in a cohort of CCLE patients and healthy controls. Unbiased clustering analyses 
identifies a “disease” based signature that distinctly separates patients from healthy controls. Func-
tional annotation of CCLE-blood differentially expressed genes (DEGs) using DAVID and Metacore 
highlight enrichment of a dysregulated immune response with prominent Type I interferon associ-
ation as well as apoptosis and cellular breakdown processes. There is a 26% overlap of the CCLE 
blood and lesional skin transcriptional profile from a previous analysis by our group. Two of the 
four transcriptional “hot spots” (chromosomal regions harboring statistically increased numbers of 
CCLE blood DEGs) overlap with previously identified CCLE skin transcriptionally active regions. 
These “hot spots” offer prioritized loci for downstream fine mapping studies in the search for CCLE 
specific susceptibility loci. Overall, these data provide further insights regarding the molecular 
genetic basis of disease heterogeneity in lupus.    
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Serum levels of soluble PD-1 and PD-L2 correlate with disease severity in systemic sclerosis
A Yoshizaki and S Sato Dermatology, University of Tokyo Graduate School of Medicine, 
Tokyo, Japan
Purpose: The programmed death-1 (PD-1) which mainly expresses on T cells and its ligand, PD-L1 
and PD-L2, show a co-inhibitory effect to T cells, resulting in prevention of excessive immune 
injury. While PD-L1 expresses on both hematopoietic and nonhemopoietic cells, PD-L2 expression 
is thought to be restricted to antigen-presenting cells (APCs), including B cells. PD-1/PD-Ls has 
two forms of expression, a membrane bound form and a soluble form. Many studies have been 
shown that soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) can promote T cell responses through 
blocking PD-1/PD-Ls pathway. However, there is no report about the biological function of sPD-L2. 
Systemic sclerosis (SSc) is generally regarded as an autoimmune disorder because of the presence of 
autoantibodies. Although the pathogenesis of SSc remains unclear, previous studies have suggested 
that B cells play an important role in disease development and progression. In this study, we focused 
on the serum levels of sPD-1 and sPD-L2 in SSc to investigate the relationship of PD-1/PD-L2 and 
disease severity. Methods: Serum levels of sPD-1 and sPD-L2 were examined in SSc (n=94) and 
healthy controls (n=25) by enzyme-linked immunosorbent assay. We also examined sPD-1 and 
sPD-L2 levels in bleomycin-induced SSc model mice. Results: Serun levels of sPD-1 and sPD-L2 in 
SSc were significantly higher than in healthy controls (p<0.01). SSc patients with elevated serum 
levels of sPD-1 and sPD-L2 had significantly higher frequency of diffuse cutaneous SSc and more 
frequent involvement of pitting scar/ulcer and pulmonary fibrosis than those with normal levels 
(p<0.05). Serum levels of sPD-1 and sPD-L2 significantly correlated positively with modified Rod-
nan total skin thickness score, serum levels of IgG, anti-topoisomerase I antibodies, and C-reactive 
protein and correlated inversely with %VC and %DLco. In bleomycin-induced SSc model mice, 
serum sPD-1 and sPD-L2 levels were higher than in control mice (p<0.01). Conclusion: These results 
suggest that elevation of serum levels of sPD-1 and sPD-L2 are associated with the disease severity.   
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Desmoglein 3 chimeric autoantibody receptor T cells: A novel strategy for immunotherapy 
of pemphigus vulgaris
C Ellebrecht, MT Cho, X Mao, VG Bhoj, C Tsai, S Nunez-Cruz, MC Milone and AS Payne 
Dermatology and Pathology, U of Pennsylvania, Philadelphia, PA
Pemphigus vulgaris (PV) is a potentially fatal blistering skin disease caused by autoantibodies 
(autoAbs) to desmoglein (Dsg) 3. Therapy for PV relies on general immunosuppression, risking severe 
infection with chronic use. Recently, chimeric antigen receptor (CAR) T cells have revolutionized 
cancer immunotherapy. CAR T cells kill antigen-expressing cancer cells and produce memory CAR 
T cells, leading to durable remission of even late-stage cancers. To evaluate this potent approach 
for PV, we engineered a series of Dsg3 chimeric autoAb receptors (CAARs), consisting of various 
Dsg3 extracellular (EC) domains fused to either T or NK receptor cytoplasmic signaling domains. In 
chromium release assays, primary human T cells expressing Dsg3 CAARs specifically kill target cells 
expressing surface anti-Dsg3 EC1, EC2, or EC3 autoAbs, with the most broad and potent cytolysis 
by the Dsg3 EC1-4 CAAR using the T cell CD137CD3ζ signaling domain (p=0.0001). Off-target 
toxicity was not observed, as Dsg3 CAAR T cells do not kill Fc-receptor+ cells coated with Dsg3 
autoAbs or human keratinocytes whose desmosomal cadherins might interact with the Dsg3 CAAR. 
Live imaging TIRF microscopy reveals that autoAb binding by the Dsg3 CAAR forms supramolecular 
activation complexes, with segregation of the CAAR away from CD45, a regulator of T cell receptor 
activation. In a preclinical PV NSG mouse model, bioluminescent AK23 (anti-EC1 surface IgG+) 
hybridoma cells were efficiently killed by Dsg3 CAAR (p=0.0015), resulting in prolonged survival 
of CAAR-treated versus control mice (p=0.016) without skin toxicity. CAAR T cells represent a novel 
strategy for PV therapy that specifically targets autoantigen-specific B cells and could readily be 
applied to other autoAb-mediated diseases.    
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Comparison of anti-desmoglein B cell repertoire and anti-desmoglein antibody repertoire 
in pemphigus patients
J Chen,1 Q Zheng,1 C Ellebrecht,1 CM Hammers,3 H Tang,2 C Lin,1 L Komorowski4 and 
JR Stanley1 1 Univ. of Pennsylvania, Philadelphia, PA, 2 Wistar Institute, Philadelphia, PA, 
3 University of Lübeck, Lübeck, Germany and 4 Institute of Experimental Immunology, 
EUROIMMUN AG, Luebeck, Germany
Autoantibodies against desmoglein 1 (Dsg1) or Dsg3 cause skin blistering in pemphigus foliaceus 
(PF) and vulgaris (PV) respectively. Although anti-Dsg B cell repertoires have been characterized 
by antibody phage display (APD), heterohybridoma, or EBV immortalization techniques, these 
methods only show potential antibody coding sequences but do not indicate which antibodies are 
actually secreted (as opposed to being, for example, memory B cell receptors) or the relative amount 
of each antibody in serum. Here, we applied high resolution tandem mass spectrometry (MS) on 
Dsg-affinity purified antibodies to characterize circulating autoantibodies in a PF and a PV patient. 
A bioinformatics algorithm with strict filters was used to identify the VH-CDR3 peptide sequences 
which are the signatures of clonal antibodies. In the PF patient we found 4 APD anti-Dsg1 clones, 
of which only 1 was pathogenic when produced recombinantly and injected into normal human 
skin. By MS we found only one antibody clone whose VH-CDR3 matched that of the pathogenic 
APD clone, but none that matched the others. In similar studies with a PV patient we found 7 anti-
Dsg3 APD clones, of which only 2 were identified as circulating antibodies by MS. To determine 
if there were other circulating antibodies not identified by APD clones, we used next generation 
sequencing of the total IgG mRNA repertoire from blood B cells from the PV patient as a reference 
database for MS. With this database we identified 7 Dsg3-specific antibodies with unique CDR3s, 
of which 5 were not found by APD. However, MS indicated one major clonal antibody (about 
5 times the amount of the 2nd most abundant clone identified) which was also found by APD. 
These results indicate that the B cell repertoire and the antibody repertoire in pemphigus are both 
oligoclonal but not completely overlapped. There is a clonally dominant serological autoimmune 
response in pemphigus.    
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B-cell profiling to predict clinical response following Rituximab therapy in patients with 
autoimmune blistering diseases
S Booker,1 B Bradley,1 B Neary,2 C Wei,2 I Sanz2 and RJ Feldman1 1 Dermatology, Emory 
University, Atlanta, GA and 2 Rheumatology, Emory University, Atlanta, GA
Autoimmune blistering diseases (AIBD) are an uncommon group of immunologically mediated dis-
eases which can affect both skin and mucous membranes. The importance of B cells in development 
and perpetuation of AIBD has been demonstrated by increased rates of clinical remission following 
B cell depletion therapy with rituximab (Rtx). However many patients will relapse in months to 
years following therapy with Rtx and the ability to predict clinical response is lacking. We sought 
to evaluate changes in B cell subsets as a way to develop predictive models of response to therapy. 
Using multichromatic flow cytometry, we phenotypically characterized patients with pemphigus, 
bullous pemphigoid, and mucous membrane pemphigoid pretreatment and following therapy with 
Rtx. At pretreatment, patients with AIBD exhibited a distinct B-cell phenotype as compared to 
healthy controls, with significant increases in switched memory IgD- CD27+ and plasmablast 
subsets CD27++ CD38++ with a contraction in the naïve/transitional compartment IgD+ CD27-. 
The switched memory population demonstrated an activated phenotype defined by decreased 
expression of CD21, CD24 and increased expression of CD95. Following rituximab therapy and B 
cell reconstitution, patients were found to have reduced memory subsets compared to pretreatment 
along with expanded transitional cell populations. However, the residual switched memory subsets 
exhibited an even higher activated profile compared with pretreatment, and frequencies were 
increased in pemphigus patients who relapsed compared to those achieving remission. These data 
suggest that switched memory B cells may play an important role in contributing to plasmablast 
populations in active disease and during relapse post Rtx. Ongoing characterization of repopulating 
B cells using next generation sequencing should uncover whether disease relapses correlate and 
are preceded by re-expansion of pre-existing memory clones.    
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Protective role of mast cells in development of lupus erythematosus-like skin lesions in 
MRL-lpr/lpr mice
Y Inaba,1 T Yoshimasu,2 N Kanazawa1 and F Furukawa1 1 Dermatology, Wakayama Medical 
University, Wakayama, Japan and 2 Dermatology, Arida Municipal Hospital, Wakayama, 
Japan
MRL-lpr/lpr (MRL/lpr) mice are known as a lupus model. Although massive infiltration of mast 
cells (MCs) is observed in the dermis of their lesional skin, roles of these MCs are obscure. There-
fore, MC-deficient MRL/lpr mice were generated. MRL/lpr mice were mated with MC-deficient 
C57BL/6J-KitW-sh/W-sh mice and the G1 offspring was 10 times backcrossed with the parental MRL/
lpr to obtain G10 offspring. The G10 offspring comprised 3 genotypes, MRL/lpr-Kit+/+, MRL/lpr-
Kit+/W-sh and MRL/lpr-KitW-sh/W-sh. The former two types form MRL/lpr mice with MCs, while the last 
type represents MRL/lpr mice without MCs. By comparison of the developmental course of skin 
lesions in the two groups, skin lesions developed earlier in MRL/lpr mice without MCs than in the 
others, and regressed spontaneously since 9 months after birth. By histological examination, MCs 
were completely absent in the skin of MRL/lpr mice without MCs, while they were observed almost 
similarly in the skin lesions of MRL/lpr mice with MCs. The number of infiltrating MCs significantly 
increased in association with the severity of skin lesions in MRL/lpr mice with MCs. In contrast, no 
obvious changes were observed in infiltration of other inflammatory cells between MRL/lpr mice 
with MCs and the others. By RT-PCR analysis of the dorsal skin, IL-1α, IL-4, IL-10, IL-33, IFNα, 
IFNγ, TNFα, TGFβ productions were significantly elevated in MRL/lpr mice without MCs compared 
with the others. Survival rate of MRL/lpr mice with MCs was significantly higher than that of the 
others. However, serum anti-nuclear antibody titer estimated by the fluoro-HEPANA test showed 
no apparent difference between them, and serum anti-dsDNA antibody level measured by ELISA 
was rather significantly higher in MRL/lpr mice with MCs than the others. Collectively, MCs are 
suggested to suppress the development of LE-like skin lesions in MRL/lpr mice, possibly by regulating 
cytokine production in the lesional skin.    
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In vitro skin irritation and potential efficacy of a novel compound for localized treatment 
of psoriasis
M Gujjar,3 JL Arbiser1, 4, 2, R Coulon2 and AK Banga3 1 Emory University, Atlanta, GA, 2 
Accuitis, Inc, Cumming, GA, 3 Pharmaceutical Sciences, Mercer University, Atlanta, GA and 
4 Atlanta VA Medical Center, Atlanta, GA
Psoriasis is a condition characterized by formation of white scaly patches on the skin. Current 
treatment options include topical glucocorticoids which offer relief but have several side effects, 
such as dermal atropy. Pentaerythritol tetrakis (3,5-di-tert-butyl-4-hydroxyhydrocinnamate) (PTTC) 
is a cinnamate tetraester which may be used as a novel topical treatment for psoriasis with less 
side effects. The purpose of this study was to determine the skin irritation and potential efficacy 
of PTTC using in vitro cell culture models. MatTek ™ Corporation has developed a cell culture 
model derived from human keratinocytes that mimics skin both morphologically and metabolically. 
Briefly, each cell insert was exposed to neat PTTC as well as PTTC topical emulsion, washed, and 
incubated overnight. An MTT assay was performed to determine cell viability; viability less than 50% 
was considered irritant. A psoriatic skin model derived from psoriatic fibroblasts is also available. 
The skin inserts were dosed with a control untreated group, neat PTTC, and PTTC emulsion for 96 
hours. Cell supernatant was collected and IL-6 levels were measured by ELISA as an endpoint to 
determine efficacy. The FDA requires that all new drugs be non-irritant to skin, thus an irritation 
assay was performed in cell culture. PTTC alone as well as topical PTTC emulsion formulation 
were found to be nonirritant with cell viability of 69.0 ± 5.64% and 74.6 ± 5.03%, respectively. 
Research indicates that psoriatic patients have elevated IL-6 levels, therefore IL-6 was chosen as an 
endpoint to determine efficacy. The basal level for untreated psoriatic skin was found to be 141.69 
± 8.41 pg/mL. Treatment with PTTC slightly reduced IL-6 levels to 122.06 ± 17.59 pg/mL, whereas 
treatment with PTTC emulsion significantly reduced IL-6 levels to 92.53 ± 12.74 pg/mL. PTTC was 
found to be non-irritant to human skin. PTTC emulsion reduced IL-6 levels, suggesting potential 
efficacy in the treatment of psoriasis.    
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Activity of interferons beta and gamma in dermatomyositis skin is correlated with charac-
teristic pathologic features
H Wheeler,1 K Rieger,3 C Lorinda,2 K Sarin1 and DF Fiorentino1 1 Dermatology, Stanford 
University, Redwood City, CA, 2 Division of Immunology and Rheumatology, Stanford 
University, Stanford, CA and 3 Dermatopathology, Stanford University, Stanford, CA
Interferon (IFN) signaling is upregulated in dermatomyositis (DM) skin, but their relation to classic 
histopathologic features is unknown. Thirty-nine skin biopsies from patients with dermatomyositis 
(DM) were subjected to gene expression analysis using Affymetrix arrays as well as histologic analysis 
by a blinded dermatopathologist. Biopsies were scored for severity of several cardinal histopatho-
logic features, including basal vacuolar change (BV) and dermal mucin deposition. Approximately 
3000 genes and 1700 genes were associated with BV and dermal mucin deposition, respectively. 
Characteristic genes associated with BV were those associated with T lymphocytes, NK cells, and 
apoptosis. While dermal mucin deposition was also associated with apoptosis, the characteristic 
genes were more associated with toll-like receptors and chemokine ligands rather than T-cells or 
NK cells. Interferon (IFN) stimulated genes were present in both sets, and we further investigated the 
role for specific interferons. For each sample, we quantified IFN -a,-b,-k,-w, (type I) and -g (type II) 
transcripts using rtPCR. We assigned two IFN scores (Type I and II) based on the median expression 
of genes most attributable to Type I or Type II IFN pathways. We found that both type I and II IFN 
scores correlated with BV (p=0.0015 for both), while only type I IFN score was associated with 
mucin deposition (p<0.0001). Only IFN-g and IFN-b transcript levels mirrored the type I and II IFN 
associations, respectively. These correlations persisted in multivariate regression analyses to control 
for age, gender, race, biopsy site, and duration of disease (mucin p<0.0001; BV p=0.055). Our 
data suggest that IFN-g (possibly from cytotoxic T cells) might play a specific role in basal vacuolar 
change in DM, and that IFN-b is associated with a broader array of changes.    
065
Treg expression and function in pemphigus
C Albuquerque,1 DL Costa,2 A Turatti,1 JS Silva2 and A Roselino1 1 Medical Clinics, Division 
of Dermatology, University of Sao Paulo, Ribeirao Preto, Brazil and 2 Biochemistry and 
Immunology, University of Sao Paulo, Ribeirao Preto, Brazil
Decreased number of regulatory T cells (Treg) is described in pemphigus vulgaris (PV). We aim to 
verify Treg cells expression and function in active PV and pemphigus foliaceus (PF) and demonstrate 
Treg distribution in pemphigus skin lesion compared to perilesional sites. Blood samples of 6 PF 
and 6 PV and 12 controls were subjected to flow citometry for Treg quantification and pheno-
typing, and samples from 5 PF and 5 PV and 10 matched controls, to the cell proliferation assay 
and co-culture to investigate functional properties of Treg. For immunohistochemistry (IHC) and 
confocal microscopy, skin biopsies were collected from lesions of 4 PV and 2 PF and perilesional 
area of 5 patients. Median percentage of CD4+CD25high Treg cells in PV, PF and controls was 1%, 
1.01% and 1.57% respectively (p=0.009). We also found difference between PV and controls 
and PF and controls(p=0.05 and p=0.02). By grouping patients compared to controls, CD4+C-
D25high Treg were lower in pemphigus (p=0.0013), as well as CD4+T CD25highFoxp3+ and CD4+ 
CD25highCCR4+ cells (p=0.001 and p=0.04). In proliferation assays, there was no difference in the 
ability of Treg from patients and controls to inhibit proliferation of PBMC co-cultivated. Analysis 
of IHC staining for Foxp3 showed an infiltrate of immunostained cells, preferentially in the upper 
dermis in all samples, with equivalent infiltrate in H&E. However, perilesional biopsy samples 
showed sparse or absent staining for Foxp3, besides inflammatory infiltrate seen in H&E. Confocal 
microscopy showed CD4+CD25+ double labeling, reinforcing the presence of Treg, suggested by 
the Foxp3 staining in IHC. Treg CD4+CD25high cells are reduced in PF and PV, but proliferation 
assays suggest that function of Treg seems to be preserved in pemphigus. Treg cells are present 
mainly in the activity sites of pemphigus, which may suggest that Treg cells, decreased in the blood 
of patients, had migrated to sites of injury were they could play a regulatory role in the intensity of 
local immunopathological response.    
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Delineation of ST18 role in the pathogenesis of pemphigus vulgaris
D Vodo,1 S Geller,1 E Ben-Asher,2 T Olender,2 I Goldberg,1 J Nosgorodsky,1 A Alkelai,2 
P Tatarsky,2 T Zeeli,1 S Baum,3 A Barzilai,3 I Saleh,4 D Zillikens,4 D Lancet,2 O Sarig1 and 
E Sprecher1 1 Tel Aviv Medical Center, Tel Aviv, Israel, 2 Weizmann Institute of Science, 
Rehovot, Israel, 3 Sheba Medical Center, Tel Aviv, Israel and 4 University of Luebeck, 
Luebeck, Germany
Apart from anti-desmosomal antibodies, recent data suggest that additional factors may be involved 
in the pathogenesis of pemphigus vulgaris (PV). We previously reported that polymorphic variants 
within the ST18 transcription factor gene locus are associated with a 6-fold increased risk for PV in 
the Jewish population as well as with a more severe phenotype. In the present study, we attempted at 
delineating the role of ST18 in the pathogenesis of PV. ST18 was found to be up-regulated in the skin 
of PV patients . In addition, we found that ST18 triggered keratinocyte secretion of both TNF-α and 
IL-1α, and promoted TNF-α-induced cell apoptosis in the presence of PV serum only. In an attempt 
to identify a causal variant responsible for ST18 overexpression in PV skin, we performed targeted 
deep sequencing of the ST18 locus in 16 patients. A case-control association analysis of 789 genetic 
variants revealed a significant association between rs17315309 and PV (p=0.003) which was subse-
quently replicated in an independent set of 185 Jewish PV patients and matched controls (p<0.001). 
This variant, located in an ST18 intron, upstream to the ST18 coding sequence, resides within a p53/
p63 transcription factor binding site consensus sequence. Using a luciferase gene reporter construct 
under the regulation of this sequence, we showed that rs17315309 induced a 7-fold increase in 
ST18 promoter fragment activity, which could be attenuated or abolished by co-transfecting the 
construct together with p53- or p63-specific siRNAs, respectively. In conclusion, our data suggest 
that a PV-associated genetic variant up-regulates ST18 expression in the epidermis of PV patients, 
which in turn, may contribute to PV pathogenesis by augmenting keratinocyte susceptibility to PV 
IgG-induced apoptosis and promoting secretion of keratinocyte-derived proinflammatory cytokines.   
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Atorvastatin attenuates cholesterol loading induced neutrophil extracellular traps
M Liu1, 2, M Bashir1, 2, KJ Williams3 and V Werth1, 2 1 Dermatology, Philadelphia VAMC, 
Philadelphia, PA, 2 Dermatology, University of Pennsylvania, Philadelphia, PA and 3 
Medicine, Temple University, Philadelphia, PA
Neutrophils (PMNs) are the first line defense, but with underestimated role in autoimmune and 
cardiovascular diseases. PMNs release granule proteins and chromatin DNA into the extracellular 
space to form neutrophil extracellular traps (NETs). NETs are found in atherosclerotic lesions, and 
NETs promote thrombosis. Moreover, pharmacological inhibition of NET formation through pepti-
dyl-arginine deiminase blockade can reduce atherosclerosis and arterial thrombosis in mice. Hyper-
cholesterolemia is the underlying cause of atherosclerotic cardiovascular disease. Nevertheless, 
the effects of cholesterol loading on NET formation and the relevant cellular mechanisms have not 
been investigated. Primary PMNs were isolated from healthy donors. Cultured human HL-60 cells 
were differentiated into PMN-like cells with 1.2% DMSO. Cholesterol was delivered to primary and 
HL-60 PMNs as a water-soluble complex with meythl-β-cyclodextrin (MCD, Chol/MCD), a widely 
used methodology for loading cholesterol to cells. Treated cells were fixed and stained with Sytox 
Green, which indicates exposed nucleic acids, then assessed with a fluorescence microplate reader 
and by fluorescence microscopy. For the effects of atorvastatin, cells were pretreated before exposure 
to Chol/MCD. We found that Chol/MCD loading could induce NET formation in a dose-dependent 
manner in primary PMNs, and in HL-60 PMNs. Both findings were confirmed by examination of the 
NET structure with fluorescent microscopy. Importantly, pretreatment of PMNs with low or lower 
dose (10 or 25 μM), but not high dose (75 μM), atorvastatin, significantly attenuated cholesterol-in-
duced NETosis in vitro. Our studies indicate that cholesterol loading can induce NET formation 
in vitro. Low-dose atorvastatin can attenuate cholesterol-induced NETosis. Our results indicate a 
potential role of hypercholesterolemia in NET formation and a potential beneficial role for statins.   
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Anti-thyroid peroxidase antibodies induce similar effects on keratinocyte cell signaling as 
antibodies directed against desmoglein 3
T Sajda, K Seiffert-Sinha and AA Sinha Dermatology, University at Buffalo, Buffalo, NY
It is well established that antibodies directed against desmoglein (Dsg) 1 and 3 are capable of dis-
rupting cell-cell adhesion and cause blister formation in the autoimmune skin disease Pemphigus 
vulgaris (PV). Our lab has previously demonstrated that PV patients additionally harbor antibodies 
directed at other self-antigens, namely thyroid peroxidase (TPO) and the muscarinic acetylcholine 
receptor subtypes 3,4, and 5. We have also shown that anti-TPO antibodies are capable of disrupt-
ing cell-cell adhesion in keratinocyte monolayers, indicating a possible pathogenic role in PV. To 
determine the extent to which anti-TPO antibodies affect cell adhesion and define their putative 
role in disease, we investigated antibody binding and downstream signaling mechanisms of known 
relevance to PV. We demonstrate that anti-TPO antibodies exhibit diffuse surface staining in cultured 
keratinocytes by immuno-fluorescent microscopy. We also assessed the affect of anti-TPO antibodies 
on intracellular calcium levels and p38MAPK phosphorylation, both of which have been associ-
ated with the pathogenicity of anti-Dsg antibodies in pemphigus. We demonstrate that anti-TPO 
antibodies cause a significant increase of p38MAPK phosphorylation compared to isotype control 
(p<0.05), but to a lesser extent than AK23, a known pathogenic mouse anti-human Dsg3 antibody 
(p<0.05). Additionally, anti-TPO antibodies cause a significant increase in intracellular calcium 
compared to isotype control, comparable to the increase in calcium caused by Ak23. However, 
the increase in calcium induced by anti-TPO is rapid and sustained, whereas the calcium increase 
caused by AK23 is oscillating. Our data indicate that antibodies directed against TPO bind to a thus 
far undefined target on the keratinocyte surface and induce downstream signaling events similar 
to anti-Dsg3 antibodies. Further studies are needed to determine the target of TPO binding on the 
keratinocyte surface and the role these antibodies may play in inducing blister formation in PV.   
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IL-13 receptor alpha 1 downregulation as a protective mechanism and therapeutic target 
in pemphigus
K Seiffert-Sinha, EZ Welch, R Dey-Rao and AA Sinha Dermatology, University at Buffalo, 
Buffalo, NY
Pemphigus vulgaris (PV) is a humorally based autoimmune blistering skin disease in which an asso-
ciation between specific HLA class II alleles, DRB1*0402 and DQB1*0503, and increased risk has 
been well established. A major unknown is why healthy individuals who express these same HLA 
risk alleles (termed HLA-matched controls) do not develop disease. Genome-wide transcriptional 
analysis data from our lab recently identified a group of genes that are specifically downregulated in 
peripheral blood mononuclear cells (PBMC) of HLA-matched controls, but not in HLA-unmatched 
controls, suggesting the novel hypothesis that suppression of critical pathways in genetically sus-
ceptible individuals could function to protect from developing the autoimmune phenotype. Of 
particular interest within this “protection signature” is the IL-13 receptor α1 (IL-13Rα1) gene which 
is downregulated in HLA-matched controls vs. PV patients and HLA-unmatched controls, and also 
in remittent vs. active PV patients. The IL-13Rα1 gene encodes one component of the common 
IL-4/IL-13 receptor. Both IL-4 and IL-13 promote differentiation of Th2 cells and are essential for 
B cell activation and (auto)antibody production. We aimed to quantify the expression of IL-13Rα1 
on defined PBMC subsets at the protein level by multiparameter flow cytometry in PV patients 
(active and remittent), HLA-matched controls and HLA-unmatched controls. We find a statistically 
significant decrease of IL-13Rα1 expression that is localized to the monocyte population of matched 
controls vs. PV patients and unmatched controls (p>0.01 in both cases). Receptor expression is 
also downregulated in monocytes of remittent vs. active PV patients, suggesting that the downreg-
ulation of IL-13Rα1 on monocytes is instrumental in the protection against disease development in 
genetically susceptible, but healthy individuals, and may also play a role in reverting PV patients 
into remission. Our findings identify IL-13Rα1 as a possible therapeutic target in PV, and suggest 
that monocytes are key players in disease pathogenesis.    
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Comparative genomic analysis in autoimmune clusters with PV
P Sasankan, SY Naseer, K Seiffert-Sinha and AA Sinha Dermatology, University at Buffalo, 
Buffalo, NY
Pemphigus Vulgaris (PV) is rare autoimmune skin disease in which multiple genetic as well as 
nongenetic elements contribute to the dysregulation of immune tolerance ultimately leading to 
autoantibody formation and blistering of the skin. It is known that individuals with one autoimmune 
disease, including PV, are at higher risk for developing other autoimmune diseases. The common 
gene hypothesis states that the interaction of common genetic and transcriptional elements along 
with activation of common biological pathways may be relevant across multiple autoimmune and 
inflammatory disorders. Our lab has recently shown that PV forms a distinct disease cluster with 
thyroid disease (AITD), rheumatoid arthritis (RA), and type 1 diabetes (T1D), as well as second cluster 
with systemic lupus erythematous (SLE), RA, and AITD, suggesting the hypothesis that shared genetic 
components underlie autoimmune development in these conditions. In order to identify shared 
genes and pathways among disease clusters, we compared publicly available GWAS and DNA 
microarray data for PV, AITD, RA, T1D and SLE, including data from our own lab. Comparison of 
one publically available GWAS study in PV with GWAS studies in diseases clustering with PV reveals 
a modest degree of genomic overlap with 1-8 genes per comparison. Pathway analysis of these 
common genes reveals predominant involvement of canonical pathways involved in innate and 
adaptive immunologic processes. Comparison of differentially expressed genes (DEGs) derived from 
microarray studies in the clustered autoimmune diseases with our own list of DEGs in PV revealed 
that 5 DEGs overlap with AITD and PV, 24 DEGs overlap with SLE and PV, 26 DEGs overlap with 
RA and PV, and 109 DEGs overlap with T1D and PV. Pathway analysis of these common genes 
reveals a significant involvement of RhoA signaling in RA, SLE, and PV, as well as a significant effect 
of oxidative stress in RA, SLE, T1D, and PV. Our data indicate that autoimmune diseases that cluster 
with PV share biological pathways linked to genetic and transcriptional alterations.    
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Lineage tracing of isotype-specific autoantibody repertoires in pemphigus vulgaris
EM Mukherjee, C Ellebrecht, Q Zheng, EJ Choi and AS Payne Dermatology, U of 
Pennsylvania, Philadelphia, PA
Pemphigus vulgaris (PV) is a potentially fatal autoimmune disease of the skin and mucous mem-
branes caused by autoantibodies (autoAbs) to desmoglein (Dsg) 3 and 1. The majority of PV autoAbs 
are IgG4, less so IgG1, and >50% of patients have anti-Dsg IgA. To better understand the clonal 
relationships among autoreactive B cells in PV and how they relate to the dominant IgG4 subclass, 
we cloned human anti-Dsg3/1 IgA1, IgA2, IgG1, and IgG4 subtype-specific repertoires from 2 PV 
patients, one with new onset untreated disease and one with treated but chronic active disease, and 
combined mAb functional analysis with isotype-specific deep sequencing for comprehensive genetic 
analysis. We characterized 138, 100, 117 and 151 IgA1, IgA2, IgG1, and IgG4 clones, enriched 
from >108 screened for Dsg reactivity, which identified 13, 16, 10 and 13 H-CDR3 clonotypic 
families. 16 clonotypes were shared among isotypes, including 5 with relatives in 3-4 isotypes. In 
the patient with new onset disease, 67% of IgA1, 47% of IgA2, 77% of IgG1, and 67% of IgG4 
clonotypes had relatives in other isotypes, whereas in the patient with chronic active disease clonal 
relatives were mainly detected between anti-Dsg IgA1 and IgA2. Despite clonal relatedness, genetic 
lineage analysis revealed divergent patterns of somatic mutation that suggest independent rather than 
sequential class switch between anti-Dsg IgG1 and IgG4 . Interestingly, in chronic active disease, 
anti-Dsg IgG4 demonstrated significantly higher somatic mutations than IgG1 and IgA (median 26, 
p<0.0001), but not in new onset disease (median 11, p=0.20). Additionally, 10/10 anti-Dsg IgG4 
in chronic active disease targeted pathogenic EC1 domain of Dsg3, compared to 1/5 in new onset 
disease, with the remaining targeting EC4 (p=0.0037). Our data suggest that the anti-Dsg immune 
response shows a relatively high degree of clonal relatedness among IgA1, IgA2, IgG1 and IgG4 B 
cells, but that the various isotypes evolve from common precursors through independent pathways.   
072
A pathogenic role for IL-9 in psoriasis: IL-9 producing T cells are frequent in human psoriasis 
and IL-9 enhances dermatitis in two IL-17 dependent mouse models of psoriasiform dermatitis
A Gehad,1 C Schlapbach,2 TR Matos,1 JE Teague,1 V Huang,1 E Lowry,1 TS Kupper1 and 
R Clark1 1 Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, 
MA and 2 Dermatology, University of Bern, Bern, Switzerland
Previously considered a minor TH2 cytokine, IL-9 has now been found to enhance TH1 mediated 
anti-cancer responses, TH2 mediated helminth expulsion and TH17 mediated EAE. We recently 
found that most human IL-9 producing T cells were skin tropic, that IL-9 production was transient, 
preceded the up-regulation of other inflammatory cytokines and enhanced cytokine production from 
other T cell subsets, suggesting IL-9 may amplify inflammation. We found CD4+ IL-9 producing T 
cells were increased in human psoriatic lesional skin. We studied IL-9 in two IL-23/IL-17 dependent 
mouse models of psoriasiform dermatitis, topical imiquimod application and IL-23 injection. IL-9 
was produced early in lesional skin and preceded the up-regulation of other inflammatory cytokines. 
Blocking IL-9 by injection of neutralizing IL-9 antibody into the skin decreased psoriasiform skin 
inflammation in both models, reducing epidermal thickness, mononuclear and T cell infiltrates and 
decreasing production of IL-17A, IL-17F and IL-22. IL-9 neutralization had little effect on IL-23, 
suggesting it may act downstream of IL-23 on TH17 and TH22 cells to enhance cytokine produc-
tion. T cell depletion decreased histologic inflammation and reduced IL-9 production by 45%, 
demonstrating T cells are likely a significant source of IL-9 in these mouse models. In summary, 
we find increased numbers of IL-9 producing T cells in human psoriatic skin lesions and we find 
that IL-9 participates in initiating inflammation in two IL-17- and IL-23-dependent mouse models of 
psoriasiform dermatitis. IL-9 inhibitors have been evaluated for the treatment of allergic diseases and 
asthma. However, if we confirm a role for IL-9 in psoriasis, IL-9 inhibitors may prove to be effective 
new therapies for this and possibly other autoimmune and inflammatory diseases.    
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Unmet need for mental health care in cutaneous lupus erythematosus and dermatomyositis
JC Achtman,1 J Okawa1 and V Werth1, 2 1 Dermatology, Perelman School of Medicine, 
Philadelphia, PA and 2 Dermatology, VA Medical Center, Philadelphia, PA
The aim of this study is to characterize unmet need for mental health care in cutaneous lupus 
erythematosus and dermatomyositis. Patients in the cross sectional study were administered a 
questionnaire to detect clinical depression and/or anxiety as well as any current treatment for 
mental illness or barriers to treatment if untreated. Patients with CLE and DM suffer from decreased 
quality of life compared to the healthy population and patients with other chronic conditions. While 
psychiatric comorbidities such as depression and anxiety have been thoroughly documented in 
other chronic dermatological and rheumatological conditions, these mental health issues remain 
less well described in skin-predominant lupus erythematosus and dermatomyositis. To date, the 
literature does suggest increased rates of mood and anxiety disorders in these diseases in the context 
of decreased quality of life; however, little is known about access and barriers to and utilization of 
mental health care in this population. 47 patients with CLE and 37 patients with DM were enrolled 
in this study. Spearman’s rank correlation coefficient for depression and anxiety were 0.77 and 
0.80 (p<0.0001) for CLE and DM respectively. 34.0% (16/47) and 51.4% (19/37) of CLE and DM 
patients, respectively, met criteria for depression and/or anxiety with need for treatment. Of those 
patients, 37.5% (6/10) and 31.6% (6/19) of CLE and DM patients, respectively, were untreated for 
their mental illness. Overall, 12.8% (6/47) and 16.2% (6/37) of CLE and DM patients, respectively, 
have untreated depression and/or anxiety. Given the significant unmet need for mental health care 
in these populations and the lack of guidelines for dermatologists treating these autoimmune skin 
conditions, these findings suggest a need for improvement in awareness, screening, and referral of 
patients to appropriate psychiatric support services.    
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Epigenetic studies of oral lichen planus as a model for inflammation-mediated cancer devel-
opment via malignant reprogramming
CG Tepper,1 Y Izumiya,2 W Murphy,2 P Davari2 and N Fazel2 1 Biochemistry and Molecular 
Medicine, UC Davis, Sacramento, CA and 2 Dermatology, UC Davis, Sacramento, CA
Oral lichen planus (OLP) is a chronic inflammatory disease that is considered to be a pre-malignant 
condition. Studies of loss of heterozygosity and microsatellite instability indicate that OLP is molec-
ularly distinct from oral dysplasias and SCC. The operating hypothesis for our studies is that tumors, 
such as SCC, arise through “malignant reprogramming” driven by a combination of both genetic and 
epigenetic changes. The primary goal of this pilot study is to identify key sites of aberrant epigenetic 
regulation in OLP by defining the entire repertoire of differentially-expressed genes and regulatory 
non-coding in OLP lesions. Towards this goal, we are performing state-of-the-art next-generation 
sequencing (NGS)-based whole transcripome profiling (RNA-Seq) analyses of matched pairs of 
OLP and perilesional normal surrounding tissue samples. The specimens were sectioned for RNA 
extraction, chromatin immunoprecipitation, and immunohistological studies. Sequencing libraries 
prepared from the total RNA samples are currently being sequenced on an Illumina HiSeq 2000 
to yield ~30 million reads per sample, which will then be processed with our automated analysis 
pipeline, which incorporates several tools for data pre-processing, read alignment, estimation of 
transcript abundance, variant analysis, etc. Subsequently, integrative bioinformatics will be applied 
in order to define an OLP-specific gene expression signature, as well as application of gene set 
enrichment analysis to define potential overrepresentation of functional groups, including immune 
system and inflammatory pathway-related genes. Insight into the mechanistic basis engendering 
these expression changes will be obtained by correlation with the occurrence of somatic mutations 
(variant analysis) and epigenetic changes, such as histone modifications. We anticipate that charac-
terization of the latter will lead to the identification of the responsible histone-modifying enzymes, 
which can then be exploited as novel therapeutic targets.    
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Oxidative stress-induced calreticulin/gC1qR complex production may prevent cells from 
apoptosis: a new insight into the destruction of melanocytes
L Liu, P Song, Y Zhang, C Li and T Gao Department of Dermatology, Xijing Hospital, Fourth 
Military Medical University, Xi’an, China
Background: Reactive oxygen species (ROS) and autoimmunity interact synergistically, leading to 
the final destruction of melanocytes in vitiligo. The C1q-binding proteins calreticulin (CRT) and 
gC1qR are highly conserved ubiquitous proteins, which are putative targets for an important role in 
apoptosis. Objective: We tested the hypothesis that these proteins form a complex prevents in the 
cytoplasm as a response to oxidative stress and the formation of a cytosolic CRT/gC1qR complex 
might prevents cell apotosis by reducing gC1qR translocation into the mitochondria. Methods: To 
explore CRT/gC1qR complex function in oxidative stress mediated melanocyte damage, we detected 
the CRT, gC1qR expression patterns in keratinocytes and melanocytes, respectively. Moreover, we 
observed the localization of the CRT/gC1qR complex by Immunolocalization and conrmed using 
immunoprecipitation in vivo. Results: Total CRT levels increased in a time-dependent manner in 
human immortalized normal and vitiligo melanocytes exposed to H2O2-induced oxidative stress, 
and surface levels of CRT were increased. Similarly, the increased levels of gC1qR were detected 
laterly. Furthermore, WB analysis using antibodies to CRT or gC1qR in different subcellular fractions 
showed that gC1qR was also detected in the mitochondrial fraction of the melanocytes. In contrast, 
we found decreased transcript levels of CRT and gC1qR, and the complex (~97 kDa protein) was 
present consequently only in the cytoplasm of Hacat cells but was hardly detectable in melanocytes. 
Conclusion: These data suggest that a CRT/gC1qR complex is induced in the cytoplasm during an 
early stage of H2O2-induced oxidative stress and this complex prevents apoptosis mainly by reducing 
gC1qR translocation to the mitochondria.    
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Plumbagin was a potential therapeutic medicine for psoriasis by inhibiting the proliferation 
and secretion of inflammation cytokines of keratinocyte 
Y Zhang and G Wang Department of Dermatology, Xijing Hospital, Fourth Military Medical 
University, Xi’an, China
Plumbagin (PL), a medicinal plant-derived 1,4-naphthoquinone, has been reported to exhibit poten-
tial functions for DC-related autoimmune and inammatory diseases, but less is known about its 
mechanism of therapy .We present here first time that PL inhibits the inammatory and proliferation 
of psoriasis keratinocytes in imiquimod psoriasis mouse model. In this study, we demonstrated that 
PL inhibits the epidermal secretion inammatory cytokines IL-6IL-10IL-1aIL-17IL-23CCL20K10K-
16K17,and the epidermal thickness was reduced. The suppresses inflammatory and proliferation 
of PL expressed both in vivo and in vitro. By stimulating with IL-17 and TNF-α in hacat cell, some 
inflammation relevant cytokins had been inhibited by treat with PL. Moreover, the proliferation 
of hacat cells was inhibited by stimulating with IL-22. we assessed the effects of PL on the MAPK 
pathway; and the results indicated signicant changes were observed in the levels of phosphorylated 
ERK1/2,and p38 MAPK, which further confirmed that a decreasing tendency of phosphorylation of 
MAP kinases on imiquimod psoriasis mouse model and likewise in IL-17 and TNF-a -induced hacat 
cell line.These data suggests that PL exerts its anti-inammatory and inhibit proliferation function by 
down-regulating the expression of proinammatory mediators through inhibition of MAPK signal.   
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Defective complement inhibitory function of CD46 predisposes to bullous pemphigoid
P Qiao and G Wang Department of Dermatology, Xijing Hospital, Fourth Military Medical 
University, Xi’an, China
Bullous pemphigoid (BP) is a common and intractable autoimmune blistering skin disease. It has 
been confirmed that binding of the main autoantigen BP180 and activation of the complement 
system are the most important events in the pathogenesis of BP. CD46 is a kind of complement 
regulatory proteins (CRPs) which can negatively regulate the complement activation pathways. 
Deficiency of CD46 may be associated with lower protection of healthy cells from complement 
mediated lysis. The purpose of this study was to investigate the expression and function of CD46 
in the development of BP disease. Sections form total 10 BP patients were enrolled, Immunohis-
tochemistry and immunofluorescence were used to determine the expression level of CD46 and 
we found that CD46 expression was obviously lower in the epidermal keratinocyte of BP patients. 
Furthermore,Western blot analysis was consistent with the results noted above. In vitro studies, we 
found that interference of CD46 in Hacat cell lines could boost the complement activation and C3 
deposition induced by the pathogenetic antibody from BP patients. Most importantly, Exogenous 
CD46 molecular prevented the complement activation process on the healthy skin sections induced 
by the pathogenetic antibody from BP patients. These results suggest that altered CD46 might play 
an important role in the pathogenesis of BP and complement regulatory protein CD46 have a 
potential role in the therapy of BP.    
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Increased expression of NLRP3 inflammasome in peripheral blood mononuclear cells in 
patients with bullous pemphigoid
H Fang and G Wang Department of Dermatology, Xijing Hospital, the Fourth Military Medical 
University, Xi’an, China
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease with autoantibodies 
directed against the antigen of BP180 associated with hemidesmosomes of basal keratinocytes. 
Innate and adaptive immunity are the two arms of immune response; both are actively involved 
in BP pathogenesis. However, the role of inflammasomes in autoimmune disease is less clear than 
in autoinflamma- tion, despite the numerous effects IL-1β and IL-18 can have on shaping adaptive 
immunity. To investigate the activation of inflammasome in bullous pemphigoid,we explored the 
expression of the different components of the NLRP3 inflammasome as well as other NOD-like 
receptors(NLRs) in peripheral blood mononuclear cells (PBMCs) obtained from BP patients. Cor-
relations between NLRP3 inflammasome components’ expression and clinical disease progression 
were investigated. Further, the serum IL-1β and IL-18 levels before and after treatment in the 
patients with BP were also analyzed and compared. Our data showed that expressions of NLRP3 
inflammasome(NLRP3, Caspase-1,IL-18) were significantly upregulated in PBMC from BP patients 
compared with controls. Further, the IL-18 levels in serum and blister were positive correlated with 
the autoantibody titre of BP180-NC16A, which is associated with BP disease severity in patients. 
These results indicated that the NLRP3 inflammasome is hyperactivated in BP patients. Further 
research should fous on the mechanism of activate inflammasome in autoimmunity disease.    
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Alopecia areata skin transcriptome correlates with disease severity and response to treatment
A Jabbari,1 JE Cerise,1 J Mackay-Wiggan,1 M Duvic,2 M Hordinsky,3 VH Price,4 D Norris,5 
R Clynes1 and A Christiano1 1 Dermatology, Columbia University, New York, NY, 2 
Dermatology, MD Anderson, Houston, TX, 3 Dermatology, University of Minnesota, 
Minneapolis, MN, 4 Dermatology, University of California, San Francisco, San Francisco, CA 
and 5 Dermatology, University of Colorado, Denver, CO
Alopecia areata (AA) is a common autoimmune disease with presentations of hair loss that range 
from spontaneously resolving patches (patchy AA, AAP) to lifelong total scalp (alopecia totalis, AT) 
or total body (alopecia universalis, AU) involvement that is recalcitrant to treatment. Despite the high 
incidence and a high psychosocial burden, research into AA has lagged that of other autoimmune 
diseases. We conducted a comprehensive expression analysis of affected skin of patients with AA in 
order to identify molecular and cellular signatures that characterize the disease. Skin samples were 
taken from over 100 patients with AAP, AT, AU, or control subjects were recruited into our study 
from AA registry sites. An Alopecia Areata Disease Activity Index tool (ALADIN) was developed con-
sisting of the interferon, common gamma chain cytokine, and keratin signatures, which effectively 
clustered the samples into localized and severe forms of AA. The magnitude of the ALADIN score 
correlated with the severity of disease, with AT/AU samples exhibiting increased ALADIN signatures 
compared to AAP samples. Notably, this finding challenges the notions that long-standing AT/AU is 
irrecoverable or represents “burned-out” disease, but rather illustrates AT/AU samples exhibit more 
immunological activity than samples from AAP. Adjunctive immunohistochemical studies of skin 
sections showed increased immune infiltration in AT/AU samples compared with AAP and normal 
samples. Additionally, ALADIN was used in a clinical trial of ruxolitinib for AA and was shown to 
track with clinical response. These studies serve as a foundation to identify gene expression profiles 
that may be used to track disease in AA clinical trials, distinguish patients that progress from localized 
to more severe disease, or predict patient response to treatment.    
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Status of classification criteria for amyopathic dermatomyositis 
N Khan1, 2 and V Werth3, 1 1 Dermatology, University of Pennsylvania, Philadelphia, PA, 2 
Georgetown University School of Medicine, Washington, DC and 3 Phil VAMC, Philadelphia, 
PA
Existing classification systems for idiopathic inflammatory myopathies (IIM) fail to classify and/or 
diagnose patients with amyopathic dermatomyositis (ADM). The International Myositis Classification 
Criteria Project (IMCCP) recently set forth new classification criteria for IIM to help address this 
problem. Our study examined the clinical presentation of adult patients with dermatomyositis (DM). 
We specifically investigated the adequacy of classifying patients with ADM based on the three skin 
variables—Gottron’s sign, Gottron’s papules, and heliotrope rash—included in the EULAR/ACR 
criteria. This retrospective study included 135 adult patients with a clinical and histological diagnosis 
of DM that were enrolled in a database at the Autoimmune Skin Disease Clinic at the University of 
Pennsylvania. Skin findings were evaluated using the Cutaneous Dermatomyositis Disease Area and 
Severity Index (CDASI). A web calculator created by the IMCCP based on the EULAR/ACR criteria 
was used to determine whether patients with ADM met the suggested 55% minimum probability 
cutoff for classification. Within our database, only 64.3% of patients with ADM (n=56) would be 
classified with an IIM based on the three skin variables included in the new EULAR/ACR criteria. 
These patients were able to meet the minimum probability cutoff for classification by presenting 
with at least two of the three skin variables. The remaining 35.7% of patients with ADM did not 
have enough of the three skin variables to meet the cutoff for classification. Therefore, the three 
skin variables included in the EULAR/ACR classification criteria for IIM —Gottron’s sign, Gottron’s 
papules, and heliotrope rash—are not adequate for classifying patients with ADM. It is important 
to consider the inclusion of additional variables such as skin biopsy or other DM skin findings to 
encompass more patients with ADM within any new classification criteria for IIM and avoid the 
inclusion of mimicking skin diseases.    
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Eruptive papules in a patient with connective tissue disease
N Dolly and S Ramachandran Dermatology, New York University, New York, NY
Eruptive collagenomas are rare connective tissue nevi (harmatomas) consisting of collagen. They 
were first reported by Colomb in 1955. They are classified as eruptive, aquired or familial. Here 
we present a case of a patient with eruptive collagenomas. Case Description: A 66 year old woman 
presented with a history of lesions first noticed three to four years prior to presentation. These lesions 
were first noted on the central chest then on the upper abdomen, breasts, arms, neck and upper back. 
There was no associated pruritus, erythema, or discharge. Past medical history was significant for 
Systemic Lupus erythematosus well- controlled on oral medications. Physical examination revealed 
hundreds of tan shiny 1-2 mm firm papules of the along the chest, breasts, neck, shoulders, back, 
abdomen and upper extremities. Darrier’s sign, pseudo Darier’s sign, pustules or collarettes were 
not present. Histological examination of punch biopsies, on two separate office visits, showed an 
unremarkable epidermis and the reticular dermis was expanded by randomly arranged coarse col-
lagen bundles of various sizes. EVG stain showed decreased elastic tissue. Based on the histological 
appearance, a diagnosis of collagenoma was made. No specific treatment has been shown to be 
efficacious with this diagnosis. Trial of low dose methotrexate was unsuccessful after four months 
of therapy. Conclusion: Eruptive collagenomas are rare connective tissue nevi. There are rare case 
reports of such occurring in patients with Multiple Endocrine Neoplasia. This is the first report of 
this occurring with connective tissue disease    
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Expanded αβ T cell clones are present in the healed lesions of psoriasis and likely represent 
the autoreactive T cells of origin
TR Matos,1 JT O’Malley,1 A Gehad,1 JE Teague,1 E Lowry,1 H Robins,2 TS Kupper,1 JG Krueger3 
and R Clark1 1 Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 2 
Adaptive Biotechnologies, Seattle, WA and 3 Rockefeller University, New York, NY
Psoriasis is a uniquely human autoimmune disease mediated by IL-17 producing T cells. Prior 
studies have demonstrated CD4 and CD8 T cells producing IL-17 and/or IL-22 remained behind 
after clinical resolution of psoriatic lesions, suggesting they may represent autoreactive T cells of 
origin in psoriasis. We studied lesional and previously lesional skin in patients who had cleared 
on etanercept therapy using deep TCR sequencing and immunostaining. Expanded oligoclonal T 
cell populations were present in healed psoriatic lesions. We identified expanded T cell clones by 
immunostaining for the specific TCR Vβ and found that they produced IL-17 and/or IL-22 in active 
lesions from the same patients, suggesting they represent disease initiating T cells. Further α/δ TCR 
sequencing demonstrated that these putative disease initiating T cell clones were universally αβ T 
cells. In contrast to studies in mouse models, γδ T cells were rare in human psoriasis, previously 
lesional psoriatic skin and in healthy human skin, making up only 1.6%, 0.45% and 1.8% of the 
total T cell population respectively. By matching TCR α and β sequences of initiating clones based 
on T cell frequency, we have obtained for the first time the complete TCR sequence of putative 
initiating T cells in psoriasis. In short, we have identified and characterized the T cells of origin in 
psoriasis and find that they are universally αβ T cells producing IL-17 and/or IL-22. In dramatic 
contrast to experiments in mice, none of the initiating cells were γδ T cells and γδ T cells were rare 
in both active and cleared disease. These results show that human psoriasis is a disease mediated 
by αβ T cells. Lastly, we have identified for the first time the full TCR sequences of initiating T 
cells in psoriasis, the first step in future studies designed to identify the auto-antigen in psoriasis.   
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Bullous pemphigoid autoantibodies and complement are required for eosinophil localization 
to the dermal-epidermal junction
JW Wang,1 HM Holahan,1 R Srikantha,1 S Aust,1 K Messingham1 and JA Fairley1, 2 1 
Dermatology, University of Iowa, Iowa City, IA and 2 VA Medical Center, Iowa City, IA
Bullous pemphigoid (BP) is an autoimmune disease characterized by sub-epidermal blistering and 
antibodies (IgG and IgE) targeting adhesion proteins located at the dermal-epidermal junction (DEJ). 
Histologic examination of lesions reveals the presence of inflammatory cells, including neutrophils 
and eosinophils, and evidence of their degranulation. Using a human skin cryosection model, others 
have shown that IgG autoantibodies are critical for neutrophil localization and degranulation at the 
DEJ and subsequent formation of a subepidermal split. However, the role of eosinophils in BP is 
not well understood. Herein, we utilized a human cryosection model to investigate the role of BP 
autoantibodies and complement in eosinophil recruitment and activation at the DEJ. Characteriza-
tion of the human eosinophilic cell line, 15HL-60, confirmed expression of receptors for IgG, IgE, 
complement and expression of eosinophil granule proteins (eosinophil derived neurotoxin (EDN) 
and eosinophil peroxidase (EPX). IgG (primarily IgG2 and IgG4) and IgE were purified from well 
characterized BP sera with high autoantibody titers. As a positive control, separation at the DEJ 
was observed when human leukocytes were incubated with BP serum and human complement. 
Interestingly, BP serum and complement were both required for localization of 15-HL60 cells to 
the DEJ; however, no subepidermal separation was observed. Similarly, localization of 15HL-60 
cells to the DEJ was observed with purified IgG, but not IgE. Interestingly, 15HL-60 cells did 
not degranulate, as measured by EDN release, under any experimental conditions. These studies 
demonstrate that eosinophil localization to the DEJ, but not degranulation, is dependent on IgG 
mediated complement fixation.    
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Collagen XVII autoantibodies are present in Parkinson’s Disease patients and co-localize with 
tyrosine hydroxylase in the substantia nigra
K Messingham,1 N Narayanan,2 S Aust,1 J Helfenberger,1 M Cassell,3 S Alberico2 and 
JA Fairley1, 4 1 Dermatology, University of Iowa, Iowa City, IA, 2 Neurology, University of 
Iowa, Iowa City, IA, 3 Anatomy and Cell Biology, University of Iowa, Iowa City, IA and 4 VA 
Medical Center, Iowa City, IA
Recent data indicates a strong epidemiologic link between Parkinson’s disease (PD) and dementia 
with the autoimmune blistering disease, bullous pemphigoid (BP). Here we tested the hypothesis 
that patients with Parkinson’s disease (PD), or dementia but without BP, would have increased 
autoantibodies against the BP antigen, collagen XVII (Col XVII). Sera were obtained from 25 PD 
patients, 25 patients with non-parkinsonian dementias, and 23 age-matched controls. Levels of 
serum autoantibodies to the pathogenic region of Col XVII (NC16A) were determined by ELISA; 
reactivity to the extracellular or intracellular domains via immunoblot. Overall, 14/50 (28%) patients 
with either PD or dementia had collagen XVII autoantibodies in their sera. Of these, 1/25 demen-
tia sera and none of the PD sera had autoantibodies against NC16A. Immunoblot against the 
recombinant extracellular domain of collagen XVII revealed that 7/25 PD sera (p<0.05) and 1/25 
dementia sera exhibited autoantibody reactivity above the 95% CI established with control sera 
(n = 23). Immunoblot against the recombinant intracellular domain of collagen XVII revealed that, 
5/25 dementia sera and 2/25 PD sera displayed antibody levels above the 95% CI. Autoantibody 
binding to the substantia nigra of rat and human brain was tested by indirect immunofluorescence 
utilizing antibodies to tyrosine hydroxylase (TH) and patient sera. Antibodies in the sera of PD 
patients (n= 4) co-localized to the TH positive neurons in rat brain, as did 5/6 from patients with 
both BP and PD. Antibodies from controls (n=8) did not. Staining of substantia nigra in human 
brain confirmed these findings. These data provide novel insight into the association between BP 
and neurodegenerative disease.    
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The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis 
with increased Th17 polarization
S Noda1, 2, M Suarez-Farinas,1 KH Lee,3 K Kabashima,4 JG Krueger1 and E Guttman-Yassky1, 
2 1 Laboratory of Investigative Dermatology, The Rockefeller University, New York, NY, 
2 Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 
3 Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea (the 
Democratic People’s Republic of) and 4 Department of Dermatology, Kyoto University 
Graduate School of Medicine, Kyoto, Japan
Atopic dermatitis (AD) has a very high prevalence (7-10% of adults) in Asia, with a large unmet 
need for effective therapeutics. Earlier studies suggest that different AD phenotypes (e.g intrinsic 
AD) are associated with distinct patterns of activation of polar immune axes and corresponding 
tissue responses. While the cellular and molecular AD skin phenotypes are well defined in European 
Americans (EAs), those in other ethnicities are largely unknown. We sought to characterize the 
Asian AD skin phenotype and compare to EA AD, using lesional and non-lesional samples from 43 
AD (16 EA and 27 Asians), 10 psoriasis (all EA) and 20 healthy individuals (8 EA and 12 Asians). 
Immunohistochemistry, gene-arrays, and RT-PCR were used for cellular and molecular profiling. 
While disease severity (SCORAD) was similar between the AD groups (58.6 vs 58.0, p=0.58), 
greater acanthosis, higher ki67 counts, and frequent parakeratosis (38% vs 6%) in lesional epidermis 
characterized Asian AD (p<0.05). While Th2 skewing characterized both Asian and EA AD but 
not psoriasis patients, significantly higher Th17/IL-23 (IL-17A, CCL20, S100A7, S100A12; p<0.1), 
and lower Th1/IFN (IFNg, CXCL9, CXCL10, MX1, STAT1; p<0.05) gene inductions typified Asian 
AD. The increased epidermal hyperplasia and parakeratosis, together with the Th17 activation in 
Asian AD argue for a “psoriasis-like” phenotype, with a strong Th2 component. Indeed, a principal 
component analysis showed that Asian AD clustered between EA AD and psoriasis. As the IL-23/
Th17 axis could contribute significantly to pathogenesis of Asian AD, relative contributions of IL-23/
Th17 and Th2 axes need to be tested with appropriate targeted therapeutics.    
086
Differing polarization of γδ T cells following topical imiquimod associated with psoriasiform 
or lupus-like disease in mice
M Ghoreishi1, 3, M Zarbafian2 and JP Dutz1, 3 1 Dermatology & Skin Science, University of 
British Columbia, Vancouver, BC, Canada, 2 Vancouver Fraser Medical Program, University 
of British Columbia, Vancouver, BC, Canada and 3 Child and Family Research Institute, 
Vancouver, BC, Canada
Background: Repeated topical application of Toll like receptor-7 (TLR7) agonist (imiquimod cream, 
Aldara) induces psoriasis-like lesions in Balb/C mice. Repeated UVB irradiation of Non-obese 
diabetic (NOD), with or without imiquimod cream, results in the development of systemic lupus-
like disease characterized by the development of autoantibodies against skin antigen as well as 
the development of glomerulosclerosis. Why differing outcomes occur with varying application 
schedules of topical TLR7 agonists and in differing mouse strains is unclear. Aim: The aim of this 
study was to explore the mechanisms underlying the discordant effects of imiquimod in Balb/C 
versus NOD mice in the induction of psoriasis or lupus-like autoimmunity. Observation: Balb/C 
and NOD mice were treated with topical imiquimod cream daily for 6 days. Balb/C mice devel-
oped psoriasis- like skin lesions. Features of psoriasis did not develop in NOD mice. Histological 
evaluations revealed characteristics of psoriasis such as acanthosis, parakeratosis, hyperkeratosis, 
and cell infiltration in Balb/C but not in NOD skin. Cellular analysis of skin and skin draining LNs 
demonstrated an increased proportion of γδ T cells in skin and skin draining LNs in both strains 
of mice. While in Balb/C, the majority of γδ T cells produced IL-17, in NOD, IFNγ producing γδ T 
cells outnumbered IL-17+ γδ T cells. Additionally, imiquimod increased the relative frequency of 
granulocytes in skin and skin draining LNs in Balb/C but not in NOD. Th1 cytokines (IFNγ, TNFα, 
IL-6) were increased in NOD skin but not in Balb/C skin after imiquimod therapy. Implication: 
Subtypes of γδ T cells and their cytokines may have role in the differential induction of lupus-like 
disease or psoriasis- like disease following topical TLR7 agonist exposure. Further work is required 
to determine if these differing responses are due to environmental or genetic.    
087
Visualizing in vivo cuticular (eponychial) hemosiderin-containing deposits in patients with 
autoimmune connective tissue diseases via Prussian blue and dermoscopy
JD McBride,1 R Sontheimer2 and T Frech2 1 University of Oklahoma, Oklahoma City, OK and 
2 University of Utah, Salt Lake City, UT
Many patients present with signs and symptoms that suggest a diagnosis on the autoimmune dis-
ease spectrum. However, certain cutaneous features may help lead a clinician towards a specific 
diagnosis. During the “acute phase” of disease activity, patients with systemic sclerosis (SSc) and 
dermatomyositis (DM) have characteristic nailfold (cuticular or eponychial findings), including 
dilated capillaries and microhemorrhages. Here, we present evidence that nail fold capillary vascular 
damage and leak result in extravasated blood components that are converted into cuticular (epony-
chium) hemosoderin-containing deposits (CEHDs). These CEHDs are distal cuticular products that 
reflect the proximal nailfold microhemorrhage event. We used the mixed solution of hydrochloric 
acid and potassium ferrocyanide to stain and visualize in vivo hemosoderin deposits as “Prussian 
blue-positive” deposits on Dermoscopy in patients with autoimmune connective tissue diseases. 
Based on a review of the literature and our clinical experiences, these CEHDs are a significant 
indicator of the acute disease process in patients with autoimmune disease and should be visualized, 
at least, via dermoscopy, in order to incorporate these findings into the overall diagnostic picture.   
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Epigenetic downregulation of SFRP4 contributes to epidermal hyperplasia in psoriasis
J Bai and H Wang Shanghai Institute of Immunology, Shanghai Jiao Tong University School 
of Medicine, Shanghai, China
Psoriasis is a chronic recurrent inflammatory skin disorder characterized by the dysregulated cross-
talk between epidermal keratinocytes and immune cells, leading to keratinocyte hyperproliferation. 
Several studies demonstrated that Wnt pathway genes were differentially expressed in psoriatic 
plaques, and likely involved in the pathophysiology of the disease. However, the molecular mech-
anisms underlying the Wnt signaling regulation in epidermal hyperplasia in psoriasis remain largely 
unknown. Here we report the expression of Secreted Frizzled-Related Protein 4 (SFRP4), a negative 
regulator of the Wnt signaling pathway, was diminished in lesional skin of mouse models and 
patients with psoriasis. SFRP4 directly inhibited excessive keratinocyte proliferation evoked by 
proinflammatory cytokine in vitro. Pharmacological inhibition of the Wnt signaling or intrader-
mal injection of SFRP4 decreased the severity of psoriasiform skin phenotype in vivo, including 
decreased acanthosis and reduced leukocyte infiltration. Mechanistically, we identified that aberrant 
promoter methylation resulted in epigenetic downregulation of SFRP4 in inflamed skin of patients 
with psoriasis and IL-23-induced mouse model. Our findings suggest that this epigenetic event is 
critically involved in the pathogenesis of psoriasis and the downregulation of SFRP4 by CpG island 
methylation is one possible mechanism contributing to hyperplasia of epidermis in the disease.   
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IL-7 blockade prevents the onset of alopecia areata 
Z Dai,1 L Xing,2 A Jabbari,1 R Clynes1 and A Christiano1, 3 1 Dermatology, Columbia 
University, New York, NY, 2 Pathology, Columbia University, New York, NY and 3 Genetics 
& Development, Columbia University, New York, NY
Alopecia areata (AA) is an autoimmune disease driven by effector cytolytic T cells that infiltrate the 
hair follicle. To identify key cytokine pathways in AA, we used comparative genomics to charac-
terize the transcriptional landscape of AA lesional skin from C3H/HeJ mice as well as humans with 
AA. We detected over expression of several gc cytokines and their receptors, such as Interleukin 
7 (IL-7) and the receptor IL7RA, in both human and mouse AA skin. IL7 is a critical survival factor 
for lymphocytes, and IL-7 uses the γc chain together with IL-7Rα for signaling. Several studies have 
shown that IL-7 is associated with the development of autoimmune diseases, and that blocking IL-7 
signaling pathway in mouse models of multiple sclerosis, type 1 diabetes, and rheumatoid arthritis 
has therapeutic benefit. Transgenic mice that overexpress IL-7 in basal keratinocytes under the 
control of the human K14 promoter develop dermal and epidermal T cell infiltrates associated with 
a form of inflammatory alopecia. IL-7 may therefore be an important factor in the ability of the skin 
to maintain populations of resident lymphocytes. To assess the effect of inhibiting a potential IL-7 
mediated response in the onset of disease in C3H AA grafted mice, we utilized an IL-7Rα blocking 
mAb to inhibit IL7 signaling. After 12 weeks of treatment started at the time of grafting, none of the 
IL-7 Rα blocking-treated mice exhibited onset of AA, whereas 100% of control mice developed AA. 
Immunohistochemical staining of skin biopsies show that IL-7Rα blocking-treated mice showed a 
striking decrease in MHC-I, MHC-II and ICAM-1 expression. Treated mice exhibited reduced CD8 
effector T cells infiltrates in the skin. Collectively, our results indicate that IL-7 is a key cytokine 
for driving autoreactive effector T cells, and moreover, that blockade of the IL-7 signaling pathway 
may be an attractive therapeutic target in the treatment of AA.    
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IFN-γ pathway blockade prevents the onset of alopecia areata 
R Clynes,1 Z Dai,1 L Xing,2 A Jabbari1 and A Christiano1 1 Dermatology, Columbia University, 
New York, NY and 2 Pathology, Columbia University, New York, NY
Alopecia areata (AA) is a common autoimmune disease resulting in hair loss. Increasing evidence 
implicates inflammatory cytokines as having a crucial role in the pathogenesis of AA. We found that 
both human AA patients and the mouse model of AA reflect an IFN-γ-specific Th1 cytokine signature 
in the skin, and many of the upregulated genes in alopecic skin of both species were IFN-response 
genes, including the IFN-inducible chemokines CXCL9-11 which are ligands of CXCR3. We found 
that the expression of CXCR3 ligands, CXCL9 and CXCL10 is upregulated in the alopecic hair follicle 
from both human AA patients and the mouse model of AA, and is associated with a dense infiltrate 
of CXCR3+ T cells, suggesting a role of CXCR3 pathway in AA. IFN-γ drives several pro-inflammatory 
pathways that facilitate pathogenic recognition and activation of the adaptive and innate response. 
Previous studies have shown that IFN-γ is required for the development of AA in C3H/HeJ mice. 
IFN-γ–deficient C3H/HeJ mice are resistant to the development of AA. Likewise, when C3H/HeJ 
female mice were injected intravenously with IFN-γ, follicular MHC was induced and these mice 
demonstrated an increased rate of development of AA. To target the IFN pathway therapeutically 
in C3H/HeJ AA skin grafted mice, we utilized IFN-γ neutralizing mAb, CXCR3 blocking mAb, and 
small molecule inhibitors of the JAK1/2 kinases baricitinib that inhibit downstream effector kinases 
of the IFN gamma receptor. Systemic treatment with IFN-γ neutralizing mAb, CXCR3 blocking mAb 
or inhibitors of the JAK1/2 at the time of grafting prevented the onset of AA. Treated mice exhibited 
reduced CD8 effector T cells infiltrates in the skin and decreased expression of IFN responsive genes 
compared to control mice, demonstrating proof-of-concept for targeted inhibition of IFN-γ pathway 
in AA. Thus, blocking IFN-γ pathway using IFN-γ neutralizing mAb, CXCR3 blocking mAb or inhib-
itors of the JAK1/2 may represent a promising therapeutic approach in the treatment of human AA.   
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Anti-BP180 IgG4 autoantibodies are inhibitory in BP in BP180 humanized mouse model
Y Zuo,1 F Evangelista,1 A Guilabert,2 N Li,1 LA Diaz1 and Z Liu1 1 University of North 
Carolina, Chapel Hill, NC and 2 Hospital General de Granollers, Barcelona, Spain
Bullous pemphigoid (BP) is an autoimmune inflammatory subepidermal blistering disease associated 
with autoantibodies against two hemidesmosomal components of the basement membrane zone 
(BMZ), the BP230 and BP180. BP IgG autoantibodies mainly target the NC16A domain of BP180 and 
NC16A-specific IgG induce BP-like skin lesions in BP180 humanized mice. Subepidermal blistering 
induced by anti-NC16A IgG depends on complement, mast cells, and neutrophils. In BP patients, 
NC16A-specific IgG predominantly belong to IgG1, IgG3 and IgG4 subclasses. Since IgG4 do not 
activate complement, the exact role of NC16A-specificIgG4 in BP remains to be defined. In this 
study, we determined the role of NC16A-specific IgG4 in BP using NC16A humanized (NC16A) 
mice and highly purified anti-NC16A IgG4 from BP patients. In vitro, NC16A-specific IgG1, IgG3 
bound and activated complement at the BMZ of the NC16A mouse skin, whereas NC16A-specific 
IgG4 bound to the BMZ but did not activate complement. Preincubation with NC16A-specific 
IgG4 reduced the BMZ binding of NC16A-specific IgG1 and IgG3. In IgG passive transfer model, 
NC16A-specific IgG1 and IgG3 but not IgG4 induced BP associated with C3 deposition at the 
BMZ and elevated C5a levels in the blister cavity. Furthermore, NC16A mice, when pretreated 
with NC16A-specific IgG4, became resistant to BP induced by NC16A-specific IgG1 and IgG3. 
This in vivo inhibitory activity of NC16A-specific IgG4 was associated with reduced IgG1 and IgG3 
deposition at the BMZ and significantly reduced generation of C5a in the blister cavity. These results 
show that NC16A–specific IgG1 and IgG3 promote BP, whereas NC16A-specific IgG4 inhibit BP 
by competing for the elicitor binding site(s) in the NC16A mouse model. Our findings suggest that 
different BP180NC16A-specific IgG subclasses have different roles in BP pathogenesis and paves 
the way for NC16A-specific IgG4-centered therapies in BP.    
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Pemphigus foliaceus patients have IgG4 antibodies that recognize Amb a 1, a component 
from short ragweed pollen allergen
Y Qian, JS Jeong and LA Diaz Department of Dermatology, University of North Carolina at 
Chapel Hill, Chapel Hill, NC
The pathogenic autoantibodies in pemphigus foliaceus (PF) are mainly of the IgG4 subclass, which 
is classically associated with IgE-mediated allergic diseases. IgG4 and IgE antibodies occur in 
response to exogenous allergens or during allergen-specific immunotherapy. Chronic allergen expo-
sure stimulates a shift from IgE to IgG4 allergen-specific antibodies. We have previously shown that 
in endemic PF, the IgG4 and IgE responses to desmoglein 1 (Dsg1) cross-react with an exogenous 
allergen present in the saliva of sand flies. In this study we have assessed the reactivity of sera from 
non-endemic PF (NE-PF) (n=30), as well as, a monoclonal anti-Dsg1 antibody generated from B 
cells of a NE-PF patient by ELISA and Immunoblot against a panel of clinically relevant exogenous 
allergens used to screen allergic patients. We found that more than 80% of the NE-PF patients have 
IgG4 antibodies against whole extract of short ragweed (Ambrosia artemisiifolia) pollen. On average 
the level of antibodies in NE-PF sera is 4 times higher than those from normal control individuals 
(n=48) (p<0.01). IgG4 antibodies from most of the NE-PF sera recognize a 38kD Amb a 1 component 
from ragweed pollen allergen. The monoclonal anti-Dsg1 antibody generated from the B cells of a 
NE-PF patient also recognizes Amb a 1, and this reaction is inhibited by Dsg1 at a concentration of 
100μg/ml. Our results suggest that some IgG4 antibodies from NE-PF recognize exogenous allergens 
that cross-react with Dsg1. These findings strengthen the hypothesis that autoimmunity in PF may 
be linked to exposure to environmental allergens.    
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T-bet-deficient mice are protected from imiquimod-induced psoriasis-like dermatitis due to 
the protective IL-4 producing NKT cells
D Wu1, 2, L Han1, 2, J Deng1, 2, L Zhou,2 C Lu1 and Q Mi2 1 Guangdong Provincial Hospital 
of Chinese Medicine, Guangzhou, China and 2 Dermatology, Henry Ford Health System, 
Detroit, MI
The transcription factor T-bet is critical for Th1 polarization of CD4 T cells. It was reported that the 
expression of T-bet in the PBMCs and lesional skin were upregulated in psoriatic patients. However, 
the function of T-bet in psoriasis development is still unclear. In this study, to investigate the in vivo 
roles of T-bet in the pathogenesis of psoriasis, we induced psoriasis-like skin inflammation with 
topical application of imiquimod (IMQ) in T-bet-/- and wild type (WT) mice. We found that mice 
lacking functional T-bet were largely protected from IMQ-induced psoriasis-like dermatitis. IFNγ-, 
IL-17- and IL-22-producing T cells, including gamma/delta T cells, were dramatically reduced in 
the skin lesions from IMQ-treated T-bet-/- mice. Furthermore, IFNγ-producing T cells were signifi-
cantly reduced in spleen and lymph node, while IL-4 producing CD4 T cells and iNKT cells were 
significantly increased in T-bet-/- mice. To further investigate the role of iNKT cells in psoriasis, we 
generated T-bet.CD1d double knockout mice, which lacked iNKT cells. In contrast to the protection 
in T-bet-/- mice, T-bet.CD1dKO mice had severe IMQ-induced dermatitis compared to WT mice. 
IL-17 and IL-22-producing T cells and gamma/delta T cells were significantly increased in lymph 
nodes from T-bet.CD1dKO mice. In conclusion, our data suggest that T-bet plays critical roles 
in psoriasis development and IL-4 producing iNKT cells contribute to T-bet-deficiency-mediated 
protection from IMQ-induced psoriasis-like skin inflammation.    
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A novel pathway regulating tolerance of peripheral B lymphocytes 
N Nikbakht1 and T Manser2 1 Dermatology and Cutaneous Biology, Sidney Kimmel Medical 
College, Philadelphia, PA and 2 Microbiology and Immunology, Sidney Kimmel Medical 
College, Philadelphia, PA
B cell activating factor of the TNF family (BAFF) promotes B cell survival and is posited to regulate 
peripheral B cell tolerance. Increased BAFF levels correlate strongly with autoimmunity. Elevated 
levels of BAFF in the serum and/or skin are found in several cutaneous inflammatory disorders 
including discoid lupus erythematosus, psoriasis, scleroderma, bullous pemphigoid, and atopic 
eczema. BAFF blockade has emerged as a potential strategy to treat autoimmune disorders. In fact, 
Belimumab is the first agent to receive approval for treatment of lupus in the United States within 
the past 50 years. However, not all Belimumab treated subjects respond favorably to BAFF deple-
tion. In this study, we sought to identify the underlying mechanisms of differential responsiveness 
to BAFF elimination. We hypothesized that BAFF preferentially promotes the survival of some, but 
not all, autoreactive B cells. Using HKI (immunoglobulin heavy chain knockin) transgenic mice, an 
established model for B cell autoreactivity, we monitored the survival of B cells expressing trans-
gene-encoded autoreactive B cell receptors upon systemic BAFF depletion or supplementation. We 
identified a subset of nuclear autoantigen reactive B cells from HKI mice that do not exhibit higher 
dependency on BAFF for survival. While HKI autoreactive B cells could fully develop within a poly-
clonal B cell repertoire, they remained at a competitive disadvantage compared to non-autoreactive 
B cells. However, this competitive disadvantage was established independent of BAFF availability. 
Our data reveal the existence of autoreactive B cell subsets that are regulated by peripheral toler-
ance mechanisms independent of the BAFF pathway. It remains to be determined whether similar 
autoreactive subsets exist in patients with autoimmune disease who do not respond to Belimumab. 
Further elucidation of these subsets may prove essential in stratification of Belimumab responders 
versus non-responders as well as development of novel targeted therapies.    
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Psoriasis is a chronic inflammatory skin disease characterized by infiltration of effector CD4 T cells 
and CD8 T cells. Effector T cells (Teff) are well-known to be a major factor in the pathogenesis 
of psoriasis, producing cytokines that induce inflammation. However, it has recently been shown 
that regulatory T cells (Tregs) also play a role, as Tregs in psoriatic lesions were shown to be highly 
proliferative and to produce IL17, compared to their relatively unresponsive state in normal skin. 
The objective of our study is to identify differences in the transcriptional profile of Tregs found in 
psoriatic lesions compared to those of normal skin. To do so, an optimal protocol to sort Tregs and 
Teff from psoriasis biopsy samples was developed. We have previously shown that CD25 and CD27 
co-expression identifies skin-resident Tregs and differentiates them from Teff to a high degree of 
purity (>90%). Cells from the skin of healthy human donors or psoriatic lesion biopsies were stained 
and sorted as Tregs (CD25+CD27+) or Teff, with gating verified by an internal FOXP3 stained control. 
Once an appropriate number of Tregs and Teff were obtained from the skin sample, analysis of RNA 
was completed via RNASeq. Preliminary results demonstrate that sorting Treg and Teff cells from 
human skin for analysis by RNA-sequencing is feasible for samples. The minimal numbers of Tregs 
and Teff needed to obtain high quality RNA from healthy and diseased human skin samples was 
determined. RNA of sufficient integrity (RIN>7) for downstream RNASeq analyses was obtained 
form as few as 5000 Tregs sorted form healthy human skin sample. By characterizing the Tregs in 
psoriatic lesions and identifying transcriptional differences to those found in normal skin, we can 
better understand disease pathogenesis.    
   
